Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,039.72
-1.8%		$907.22
$661.85
▼
$1,061.57
$65.04B0.46345,850 shs74,499 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$103.13
-7.4%		$95.17
$79.52
▼
$124.00
$26.08B1.271.11 million shs2.07 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$136.80
-4.2%		$75.62
$22.28
▼
$176.66
$54.62B0.9111.38 million shs14.27 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$793.73
-1.7%		$713.83
$541.00
▼
$847.00
$81.72B0.22840,567 shs115,572 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+1.13%+2.00%+21.40%+26.66%+49.57%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-1.03%+0.46%+20.50%+16.10%+8.14%
Moderna, Inc. stock logo
MRNA
Moderna
-4.60%+7.09%+155.81%+202.54%+468.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-0.87%-2.29%+16.19%+31.38%+37.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,039.72
-1.8%		$907.22
$661.85
▼
$1,061.57
$65.04B0.46345,850 shs74,499 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$103.13
-7.4%		$95.17
$79.52
▼
$124.00
$26.08B1.271.11 million shs2.07 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$136.80
-4.2%		$75.62
$22.28
▼
$176.66
$54.62B0.9111.38 million shs14.27 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$793.73
-1.7%		$713.83
$541.00
▼
$847.00
$81.72B0.22840,567 shs115,572 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+1.13%+2.00%+21.40%+26.66%+49.57%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-1.03%+0.46%+20.50%+16.10%+8.14%
Moderna, Inc. stock logo
MRNA
Moderna
-4.60%+7.09%+155.81%+202.54%+468.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-0.87%-2.29%+16.19%+31.38%+37.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,157.5011.33% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$127.8123.93% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.10
Hold$80.53-41.13% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.60
Moderate Buy$800.360.84% Upside

Current Analyst Ratings Breakdown

Latest BNTX, REGN, ARGX, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/26/2026
argenex SE stock logo
ARGX
argenex
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,415.00
8/26/2026
argenex SE stock logo
ARGX
argenex
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$960.00 ➝ $1,400.00
8/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
8/24/2026
Moderna, Inc. stock logo
MRNA
Moderna
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$48.00 ➝ $125.00
8/24/2026
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$40.00 ➝ $77.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B15.31$21.18 per share49.08$134.54 per share7.73
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B8.03$1.22 per share84.31$81.64 per share1.26
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B28.09N/AN/A$16.93 per share8.08
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$15.53B5.26$40.89 per share19.41$308.01 per share2.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0439.9328.091.0832.19%43.59%36.66%N/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$7.83N/AN/AN/A-63.54%-6.86%-6.00%11/3/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4619.6215.711.3927.86%13.47%10.34%10/28/2026 (Estimated)

Latest BNTX, REGN, ARGX, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.3983-$2.5340-$0.1357-$3.70$180.18 million$122.31 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.47%N/A9.29%N/A

Latest BNTX, REGN, ARGX, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
7.85
7.80
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Decreased by Harvey Capital Management Inc.
August 28 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-stock-holdings-decreased-by-harvey-capital-management-inc-2026-08-28/
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Jefferies Financial Group Inc.
August 28 at 6:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-shares-acquired-by-jefferies-financial-group-inc-2026-08-28/
Empowered Funds LLC Purchases 18,345 Shares of Regeneron Pharmaceuticals, Inc. $REGN
August 28 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-purchases-18345-shares-of-regeneron-pharmaceuticals-inc-regn-2026-08-28/
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
August 27 at 6:28 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-regn-rare-disease-win-210410578.html
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
August 27 at 5:51 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/can-regeneron-regns-rare-disease-win-move-the-earnings-needle-1821012/
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
August 27 at 4:04 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines--regn-302862171.html
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
August 27 at 1:28 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-adjusts-course-124300443.html
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
August 27 at 11:26 AM  |  newsfilecorp.comN
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 27 at 10:14 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352163/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-sbs-law.html
REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
August 27 at 10:09 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
August 27 at 9:31 AM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/regeneron-pharmaceuticals-regn-adjusts-course-amid-mixed-results-in-melanoma-drug-trials-1823402/
Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman
August 27 at 8:18 AM  |  newsfilecorp.comN
Jupiter Topco LLC Makes New $90.31 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 27 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-makes-new-9031-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-27/
Quantbot Technologies LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 27 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-makes-new-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-27/
Caisse de depot et placement du Quebec Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 27 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-caisse-de-depot-et-placement-du-quebec-makes-new-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-27/
EFG International AG Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN
August 27 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-efg-international-ag-purchases-new-shares-in-regeneron-pharmaceuticals-inc-regn-2026-08-27/
Canada Pension Plan Investment Board Invests $130.89 Million in Regeneron Pharmaceuticals, Inc. $REGN
August 27 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-invests-13089-million-in-regeneron-pharmaceuticals-inc-regn-2026-08-27/
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
August 26 at 6:14 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-regn-investors-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit-302860996.html
Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
August 26 at 2:45 PM  |  barchart.comhttps://www.barchart.com/story/news/4095887/regeneron-pharmaceuticals-stock-outlook-is-wall-street-bullish-or-bearish
Robbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.
August 26 at 12:10 PM  |  newsfilecorp.comN
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
August 26 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351583/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Microsoft logo displayed on a wall-mounted plaque in a modern office lobby with glass partitions.
Microsoft Just Flipped the AI Spending Narrative Overnight
By Chris Markoch | July 30, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
argenex stock logo

argenex NASDAQ:ARGX

$1,039.72 -19.18 (-1.81%)
As of 11:46 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$103.13 -8.27 (-7.42%)
As of 11:45 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$136.80 -5.97 (-4.18%)
As of 11:46 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$793.73 -13.98 (-1.73%)
As of 11:45 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas